Methods We retrospectively reviewed medical records of patients who received splenectomy as part of cytoreductive surgery in advanced ovarian cancer from 2007–2022. Patients were divided into the parenchymal invasion group and capsular/hilar invasion group. Clinical characteristics including histologic invasion patterns and survival outcomes were analyzed.

Results A total of 100 ovarian cancer patients received splenectomy: 55(55%), 40(40%) and 5(5%) cases were performed during primary debulking surgery, interval debulking surgery and at the time of disease recurrence respectively. The median age was 54.5 yrs, and all patients had FIGO stage III–IV disease. 27(27%) patients had parenchymal invasions and all the lesions were accompanied by capsular or hilar metastasis without solitary parenchymal invasion. Among the patients with primary disease(n=95), 42(44.2%) patients had stage IV disease including 17(17.8%) patients with splenic parenchymal metastasis. There was no difference in residual disease (p=0.392), progression-free survival (p=0.339) and overall survival(p=0.841) between the patients with parenchymal invasion and capsular/hilar metastasis.

Conclusions Although splenic parenchymal metastasis reflected widespread tumor dissemination, all the lesions were followed by hilar or capsular involvement and surgically treatable disease. The prognosis of splenic parenchymal metastasis was not inferior to the capsule or hilar invasion, therefore, it needs to be considered as FIGO stage IIIC disease.

Objectives We analyzed the survival outcomes of patients with epithelial ovarian, peritoneal, or fallopian tube cancer (EOPFTC) with BRCA1/2 mutations and the clinical factors associated with the prognosis of these cancers.

Methods Based on the data collected from Clinical Data Warehouse of Catholic university of Korea, we investigated patients who had been diagnosed and treated for EOPFTC, and undergone germline BRCA test in 6 hospitals between January 2012 and December 2019.

Results In total, 378 patients were identified and 76 (20.1%) women carried BRCA 1/2 mutation. There was no significant difference in progression-free survival (PFS; p = 0.562) and overall survival (p = 0.677) between BRCA 1/2 mutation and wild-type groups. In multivariate analysis, however, PFS of BRCA 1/2 mutation group for 18 month from primary treatment was significantly superior to wild-type group (p = 0.024). In subgroup analysis for high grade serous carcinoma patients, BRCA 1/2 mutation was an independent favorable prognostic factor for PFS (p = 0.035). Subgroup analysis for stage III to IV disease also demonstrated an independent PFS gain in patients with BRCA 1/2 mutation (p = 0.015). Neoadjuvant chemotherapy as primary treatment was related with poor PFS (p < 0.001) and reduced OS (p = 0.005).

Conclusions Germline BRCA 1/2 mutation improved short-term PFS in patients with EOPFTC. Elevated initial CA125 level and primary neoadjuvant chemotherapy were related to poor prognosis.

Objectives HER2 targeted drugs are increasingly introduced in non-breast cancers, yet studies on HER2 expression in ovarian cancer patients is lacking. Therefore, we studied HER2 receptor status and its dynamic change in ovarian cancer patients, a